Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

Next Previous
X
Search
Trial Profile

A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms JUNIPERA
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 15 Nov 2023 Results of post-hoc analysis investigating the validity of JSpADA for children with ERA and JPsA in a prospective clinical trial setting using data from this study, presented at the ACR Convergence 2023
    • 03 Jun 2023 Results of efficacy and safety through 156 weeks from this core study and LTE study presented at the 24th Annual Congress of the European League Against Rheumatism
    • 14 Nov 2022 Results assessing the effect of SEC on axial and peripheral manifestations in active ERA and JPsA patients presented at the ACR Convergence 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top